Overview on biomarkers for immune oncology drugs DOI Creative Commons
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: 6

Published: March 17, 2025

Although immune checkpoint inhibitors (ICIs) are widely used in clinical oncology, less than half of treated cancer patients derive benefit from this therapy. Both tumor- and host-related variables implicated response to ICIs. The predictive value PD-L1 expression is confined only several types, so molecule not an agnostic biomarker. Highly elevated tumor mutation burden (TMB) caused either by excessive carcinogenic exposure or a deficiency DNA repair reliable indicator for ICI efficacy, as exemplified tumors with high-level microsatellite instability (MSI-H). Other potentially relevant tumor-related characteristics include gene signatures, pattern infiltration cells, and, perhaps, some immune-response modifying somatic mutations. Host-related factors have yet been comprehensively considered trials. Microbiome composition, markers systemic inflammation [e.g., neutrophil-to-lymphocyte ratio (NLR)], human leucocyte antigen (HLA) diversity may influence the efficacy Studies on biomarkers likely reveal modifiable host characteristics, which can be utilized direct antitumor defense. Examples latter approach priming therapy cytotoxic drugs elevation microbiome modification.

Language: Английский

Overview on biomarkers for immune oncology drugs DOI Creative Commons
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: 6

Published: March 17, 2025

Although immune checkpoint inhibitors (ICIs) are widely used in clinical oncology, less than half of treated cancer patients derive benefit from this therapy. Both tumor- and host-related variables implicated response to ICIs. The predictive value PD-L1 expression is confined only several types, so molecule not an agnostic biomarker. Highly elevated tumor mutation burden (TMB) caused either by excessive carcinogenic exposure or a deficiency DNA repair reliable indicator for ICI efficacy, as exemplified tumors with high-level microsatellite instability (MSI-H). Other potentially relevant tumor-related characteristics include gene signatures, pattern infiltration cells, and, perhaps, some immune-response modifying somatic mutations. Host-related factors have yet been comprehensively considered trials. Microbiome composition, markers systemic inflammation [e.g., neutrophil-to-lymphocyte ratio (NLR)], human leucocyte antigen (HLA) diversity may influence the efficacy Studies on biomarkers likely reveal modifiable host characteristics, which can be utilized direct antitumor defense. Examples latter approach priming therapy cytotoxic drugs elevation microbiome modification.

Language: Английский

Citations

0